Deodhar A, et al. - Longer-term pooled safety and tolerability data for secukinumab across three indications [up to 5 years of treatment in psoriasis (PsO) and psoriatic arthritis (PsA); up to 4 years in ankylosing spondylitis (AS)] were reported from 21 randomized controlled clinical trials. This analysis included a total of 5181 patients from PsO clinical trials, 1380 patients from PsA clinical trials, and 794 patients from AS clinical trials representing secukinumab exposures of 10,416.9, 3866.9, and 1943.1 patient-years, respectively, and post-marketing data from patients with a cumulative exposure to secukinumab of ~ 96,054 patient-years. Over long-term treatment, secukinumab had a favorable safety profile in patients with PsO, PsA, and AS. In line with previous reports, this comprehensive assessment provides valuable evidence on the comprehensive safety profile of secukinumab in patients with PsO, PsA, and AS, that supports its long-term use in these chronic conditions.